@article{LiaqatSednevStilleretal.2021,
  author    = {Liaqat, Anam and Sednev, Maksim V. and Stiller, Carina and H{\"o}bartner, Claudia},
  title     = {RNA-cleaving deoxyribozymes differentiate methylated cytidine isomers in RNA},
  series = {Angewandte Chemie International Edition},
  volume    = {60},
  journal   = {Angewandte Chemie International Edition},
  doi       = {10.1002/anie.202106517},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-256519},
  pages     = {19058-19062},
  year      = {2021},
  abstract  = {Deoxyribozymes are emerging as modification-specific endonucleases for the analysis of epigenetic RNA modifications. Here, we report RNA-cleaving deoxyribozymes that differentially respond to the presence of natural methylated cytidines, 3-methylcytidine (m\(^3\)C), N\(^4\)-methylcytidine (m\(^4\)C), and 5-methylcytidine (m\(^5\)C), respectively. Using in vitro selection, we found several DNA catalysts, which are selectively activated by only one of the three cytidine isomers, and display 10- to 30-fold accelerated cleavage of their target m\(^3\)C-, m\(^4\)C- or m\(^5\)C-modified RNA. An additional deoxyribozyme is strongly inhibited by any of the three methylcytidines, but effectively cleaves unmodified RNA. The mXC-detecting deoxyribozymes are programmable for the interrogation of natural RNAs of interest, as demonstrated for human mitochondrial tRNAs containing known m\(^3\)C and m\(^5\)C sites. The results underline the potential of synthetic functional DNA to shape highly selective active sites.},
  language  = {en}
}
@article{LiaqatSednevStilleretal.2021,
  author    = {Liaqat, Anam and Sednev, Maksim V. and Stiller, Carina and H{\"o}bartner, Claudia},
  title     = {RNA-Cleaving Deoxyribozymes Differentiate Methylated Cytidine Isomers in RNA},
  series = {Angewandte Chemie International Edition},
  volume    = {60},
  journal   = {Angewandte Chemie International Edition},
  number    = {35},
  doi       = {10.1002/anie.202106517},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-254544},
  pages     = {19058-19062},
  year      = {2021},
  abstract  = {Deoxyribozymes are emerging as modification-specific endonucleases for the analysis of epigenetic RNA modifications. Here, we report RNA-cleaving deoxyribozymes that differentially respond to the presence of natural methylated cytidines, 3-methylcytidine (m\(^3\)C), N\(^4\)-methylcytidine (m\(^4\)C), and 5-methylcytidine (m\(^5\)C), respectively. Using in vitro selection, we found several DNA catalysts, which are selectively activated by only one of the three cytidine isomers, and display 10- to 30-fold accelerated cleavage of their target m\(^3\)C-, m\(^4\)C- or m\(^5\)C-modified RNA. An additional deoxyribozyme is strongly inhibited by any of the three methylcytidines, but effectively cleaves unmodified RNA. The m\(^X\)C-detecting deoxyribozymes are programmable for the interrogation of natural RNAs of interest, as demonstrated for human mitochondrial tRNAs containing known m\(^3\)C and m\(^5\)C sites. The results underline the potential of synthetic functional DNA to shape highly selective active sites.},
  language  = {en}
}
@article{KabingerStillerSchmitzovaetal.2021,
  author    = {Kabinger, Florian and Stiller, Carina and Schmitzov{\´a}, Jana and Dienemann, Christian and Kokic, Goran and Hillen, Hauke S. and H{\"o}bartner, Claudia and Cramer, Patrick},
  title     = {Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis},
  series = {Nature Structural \& Molecular Biology},
  volume    = {28},
  journal   = {Nature Structural \& Molecular Biology},
  doi       = {10.1038/s41594-021-00651-0},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-254603},
  pages     = {740-746},
  year      = {2021},
  abstract  = {Molnupiravir is an orally available antiviral drug candidate currently in phase III trials for the treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA mutations and impairs SARS-CoV-2 replication in animal models and in humans. Here, we establish the molecular mechanisms underlying molnupiravir-induced RNA mutagenesis by the viral RNA-dependent RNA polymerase (RdRp). Biochemical assays show that the RdRp uses the active form of molnupiravir, β-d-\(N^4\)-hydroxycytidine (NHC) triphosphate, as a substrate instead of cytidine triphosphate or uridine triphosphate. When the RdRp uses the resulting RNA as a template, NHC directs incorporation of either G or A, leading to mutated RNA products. Structural analysis of RdRp-RNA complexes that contain mutagenesis products shows that NHC can form stable base pairs with either G or A in the RdRp active center, explaining how the polymerase escapes proofreading and synthesizes mutated RNA. This two-step mutagenesis mechanism probably applies to various viral polymerases and can explain the broad-spectrum antiviral activity of molnupiravir.},
  language  = {en}
}